Title: Mechanistic insights into xanthine oxidoreductase from development studies of candidate drugs to treat hyperuricemia and gout.
Journal: Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry20150101
Title: QT/QTc study conducted in Japanese adult healthy subjects: a novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation.
Journal: Journal of clinical pharmacology20140401
Title: Effects of topiroxostat on the serum urate levels and urinary albumin excretion in hyperuricemic stage 3 chronic kidney disease patients with or without gout.
Journal: Clinical and experimental nephrology20140101
Title: Study on species differences in nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Journal: Archives of toxicology20110501
Title: Establishment of simultaneous treatment model with citrate for preventing nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Journal: Drug and chemical toxicology20110401
Title: Study on toxicological aspects of crystal-mediated nephrotoxicity induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Journal: Drug and chemical toxicology20110401
Title: FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase.
Journal: The Journal of pharmacology and experimental therapeutics20110101
Title: Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected].
Journal: Bioorganic & medicinal chemistry letters20091101
Title: FYX-051, a xanthine oxidoreductase inhibitor, induces nephropathy in rats, but not in monkeys.
Journal: Toxicologic pathology20090601
Title: [Inhibitors of xanthine oxidoreductase].
Journal: Nihon rinsho. Japanese journal of clinical medicine20080401
Title: [New antihyperuricemic medicine: febuxostat, Puricase, etc].
Journal: Nihon rinsho. Japanese journal of clinical medicine20080401
Title: Crystal structures of mammalian xanthine oxidoreductase bound with various inhibitors: allopurinol, febuxostat, and FYX-051.
Journal: Journal of Nippon Medical School = Nippon Ika Daigaku zasshi20080201
Title: Characterization of N-glucuronidation of 4-(5-pyridin-4-yl-1H-[1,2,4]triazol-3-yl) pyridine-2-carbonitrile (FYX-051): a new xanthine oxidoreductase inhibitor.
Journal: Drug metabolism and disposition: the biological fate of chemicals20071201
Title: Strain differences in the responsiveness between Sprague-Dawley and Fischer rats to nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor.
Journal: Toxicology and applied pharmacology20061215
Title: Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl)pyridine-2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides.
Journal: Drug metabolism and disposition: the biological fate of chemicals20061101
Title: Simultaneous treatment with citrate prevents nephropathy induced by FYX-051, a xanthine oxidoreductase inhibitor, in rats.
Journal: Toxicological sciences : an official journal of the Society of Toxicology20050901
Title: The crystal structure of xanthine oxidoreductase during catalysis: implications for reaction mechanism and enzyme inhibition.
Journal: Proceedings of the National Academy of Sciences of the United States of America20040525
Title: An extremely potent inhibitor of xanthine oxidoreductase. Crystal structure of the enzyme-inhibitor complex and mechanism of inhibition.
Journal: The Journal of biological chemistry20030117
Title: Sato T, et al. Discovery of 3-(2-cyano-4-pyridyl)-5-(4-pyridyl)-1,2,4-triazole, FYX-051 - a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia [corrected Bioorg Med Chem Lett. 2009 Nov 1;19(21):6225-9.
Title: Matsumoto K, et al. FYX-051: a novel and potent hybrid-type inhibitor of xanthine oxidoreductase. J Pharmacol Exp Ther. 2011 Jan;336(1):95-103.
